BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 8813472)

  • 1. Somatostatin receptor: scintigraphy and radionuclide therapy.
    Krenning EP; Kooij PP; Pauwels S; Breeman WA; Postema PT; De Herder WW; Valkema R; Kwekkeboom DJ
    Digestion; 1996; 57 Suppl 1():57-61. PubMed ID: 8813472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
    Wangberg B; Forssell-Aronsson E; Tisell LE; Nilsson O; Fjalling M; Ahlman H
    Br J Cancer; 1996 Mar; 73(6):770-5. PubMed ID: 8611378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results.
    Krenning EP; Kwekkeboom DJ; Oei HY; de Jong RJ; Dop FJ; Reubi JC; Lamberts SW
    Ann N Y Acad Sci; 1994 Sep; 733():416-24. PubMed ID: 7978890
    [No Abstract]   [Full Text] [Related]  

  • 5. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
    Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
    [No Abstract]   [Full Text] [Related]  

  • 7. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
    Krenning EP; de Jong M; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; Jamar F; Pauwels S; Valkema R
    Ann Oncol; 1999; 10 Suppl 2():S23-9. PubMed ID: 10399029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.
    Schillaci O; Corleto VD; Annibale B; Scopinaro F; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
    Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
    QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide.
    Krenning EP; Valkema R; Kooij PP; Breeman WA; Bakker WH; deHerder WW; vanEijck CH; Kwekkeboom DJ; deJong M; Pauwels S
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S219-23. PubMed ID: 10604135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.
    Slooter GD; Mearadji A; Breeman WA; Marquet RL; de Jong M; Krenning EP; van Eijck CH
    Br J Surg; 2001 Jan; 88(1):31-40. PubMed ID: 11136306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of radioactive somatostatin and its analogues in the control of tumor growth.
    Krenning EP; Valkema R; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; de Jong M; Jamar F; Pauwels S
    Recent Results Cancer Res; 2000; 153():1-13. PubMed ID: 10626285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
    Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
    J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
    J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
    Pauwels S; Leners N; Fiasse R; Jamar F
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
    [No Abstract]   [Full Text] [Related]  

  • 17. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide receptor imaging and therapy.
    Kwekkeboom D; Krenning EP; de Jong M
    J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours.
    Gotthardt M; Béhé MP; Grass J; Bauhofer A; Rinke A; Schipper ML; Kalinowski M; Arnold R; Oyen WJ; Behr TM
    Endocr Relat Cancer; 2006 Dec; 13(4):1203-11. PubMed ID: 17158765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.
    Krenning EP; Kwekkeboom DJ; Bakker WH; Breeman WA; Kooij PP; Oei HY; van Hagen M; Postema PT; de Jong M; Reubi JC
    Eur J Nucl Med; 1993 Aug; 20(8):716-31. PubMed ID: 8404961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.